



Market Announcement

15 April 2024

Neurotech International Limited (ASX: NTI) – Trading Halt

Description

The securities of Neurotech International Limited ('NTI') will be placed in trading halt at the request of NTI, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Wednesday, 17 April 2024 or when the announcement is released to the market.

Issued by

ASX Compliance

15 April 2024

Sean Maloney
Adviser, Listing Compliance (Perth)
Australian Securities Exchange
Level 40, Central Park
152-158 St Georges Terrace
Perth WA 6000

BY EMAIL: tradinghaltsp Perth@asx.com.au

Dear Sir

Request for Trading Halt

Neurotech International Limited (ASX: NTI) ('Company') requests a trading halt be placed on the Company's securities pursuant to ASX Listing Rule 17.1, pending the release of the results of the Company's Phase II/III clinical trial in paediatric patients with Autism Spectrum Disorder, the top-line results for the Phase I/II Rett Syndrome clinical trial and an announcement regarding a capital raising.

The Company requests the securities remain in halt until the earlier of the release of announcements regarding the above, or the commencement of trade on Wednesday, 17 April 2024.

The Company is not aware of any reason why the trading halt should not be granted, nor is it aware of any other information necessary to inform the market about the trading halt.

This request has been authorised by Dr Thomas Duthy, Executive Director of Neurotech International Limited.

Yours Faithfully,



Alessandra Gauvin
Joint Company Secretary